Table 2

Postendoscopy GI bleeding, thromboembolism and death in propensity score-matched patients treated with warfarin and DOACs (n=10 092)

Postendoscopy GI bleedingp ValuePostendoscopy thromboembolism*p ValuePostendoscopy deathp Value
Warfarin (n=5046)605 (12.0)275 (5.4)270 (5.4)
DOACs (n=5046)506 (10.0)0.002239 (4.7)0.103239 (4.7)0.172
Rivaroxaban (n=2149)185 (8.6)<0.00190 (4.2)0.02692 (4.3)0.059
Apixaban (n=1751)183 (10.5)0.09176 (4.3)0.07999 (5.7)0.625
Dabigatran (n=805)108 (13.4)0.24624 (3.0)0.00230 (3.7)0.058
Edoxaban (n=341)30 (8.8)0.08249 (14.4)<0.00118 (5.3)1.000
  • Data are presented as n (%).

  • *Thromboembolism included cardiovascular events (n=184), cerebrovascular events (n=129), pulmonary embolism (n=57) and deep vein thrombosis (n=166).

  • DOACs, direct oral anticoagulants.